ASX:MEMMemphasys Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Memphasys Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$0.06 -0.01 (-14.08 %) (As of 05/13/2020) Add Compare Share Today's RangeA$0.06Now: A$0.06▼A$0.0750-Day RangeA$0.06MA: A$0.06▼A$0.0652-Week RangeA$0.03Now: A$0.06▼A$0.10Volume246,322 shsAverage VolumeN/AMarket Capitalization$45.99 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines Memphasys Limited, a bio-separations company, develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix that separates sperm from semen sample using electrophoresis and specialist membranes for the use in fertility treatments, including IVF for humans, as well as for artificial reproductive techniques for animals; and a polymer membrane separation technology using polyacrylamide hydrogel membranes with electrophoresis. The company was formerly known as NuSep Holdings Limited and changed its name to Memphasys Limited in July 2016. Memphasys Limited is headquartered in Homebush, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Memphasys. Previous Next 2.7 Community Rank Outperform VotesMemphasys has received 15 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMemphasys has received 13 “underperform” votes. (Add your “underperform” vote.)Community SentimentMemphasys has received 53.57% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Memphasys and other stocks. Vote “Outperform” if you believe MEM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MEM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMemphasys does not currently pay a dividend.Dividend GrowthMemphasys does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Memphasys insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Memphasys is -30.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Memphasys is -30.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMemphasys has a P/B Ratio of 4.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.54 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:MEM Previous Symbol CUSIPN/A CIKN/A Webwww.memphasys.com Phone61 2 8415 7300Debt Debt-to-Equity Ratio11.18 Current Ratio9.52 Quick Ratio7.79Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowA$0.01 per share Price / Cash Flow12.20 Book ValueA$0.01 per share Price / Book4.69Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares753,974,016Market Cap$45.99 million Next Earnings DateN/A OptionableNot Optionable Receive MEM News and Ratings via Email Sign-up to receive the latest news and ratings for MEM and its competitors with MarketBeat's FREE daily newsletter. Memphasys (ASX:MEM) Frequently Asked Questions Has Memphasys been receiving favorable news coverage? Media coverage about MEM stock has been trending negative on Friday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Memphasys earned a media sentiment score of -2.4 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news about Memphasys. Who are some of Memphasys' key competitors? Some companies that are related to Memphasys include Bellus Health (BLU), Burcon NutraScience (BU), Neuren Pharmaceuticals (NEU), IMV (IMV), Horizon Discovery Group (HZD), CorMedix (CRMD), OncoCyte (OCX), Resverlogix (RVX), Orgenesis (ORGS), Matinas Biopharma (MTNB), Predictive Technology Group (PRED), Monash IVF Group (MVF), Faron Pharmaceuticals Oy (FARN), BioTime (BTX) and Lineage Cell Therapeutics (LCTX). View all competitors. Who are Memphasys' key executives? Memphasys' management team includes the following people: Ms. Alison Mary Coutts B.E. (Chem), GDipBiotech, MBA, Exec. Chairman & Interim CEOPablo Neyertz, Director of Fin.Mr. Malcolm Coleman, Chief Financial Officer of Nusep LtdMr. Andrew Metcalfe, Company Sec. What is Memphasys' stock symbol? Memphasys trades on the ASX under the ticker symbol "MEM." What is Memphasys' stock price today? One share of MEM stock can currently be purchased for approximately A$0.06. How big of a company is Memphasys? Memphasys has a market capitalization of $45.99 million. What is Memphasys' official website? The official website for Memphasys is www.memphasys.com. How can I contact Memphasys? The company can be reached via phone at 61 2 8415 7300. This page was last updated on 7/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
